止血的小鼠模型。
Mouse models of hemostasis.
机构信息
Department of Pathology, Microbiology and Immunology, Vanderbilt University , Nashville, TN, USA.
Department of Pathology and Immunology, Washington University , St. Louis, MO, USA.
出版信息
Platelets. 2020 May 18;31(4):417-422. doi: 10.1080/09537104.2020.1719056. Epub 2020 Jan 28.
Abstract
Hemostasis is the normal process that produces a blood clot at a site of vascular injury. Mice are widely used to study hemostasis and abnormalities of blood coagulation because their hemostatic system is similar in most respects to that of humans, and their genomes can be easily manipulated to create models of inherited human coagulation disorders. Two of the most widely used techniques for assessing hemostasis in mice are the tail bleeding time (TBT) and saphenous vein bleeding (SVB) models. Here we discuss the use of these methods in the evaluation of hemostasis, and the advantages and limits of using mice as surrogates for studying hemostasis in humans.
摘要
止血是一种正常的生理过程，它会在血管损伤部位形成血栓。小鼠被广泛用于研究止血和血液凝固异常，因为它们的止血系统在大多数方面与人类相似，并且它们的基因组很容易被操纵，以创建遗传性人类凝血障碍的模型。评估小鼠止血功能最常用的两种技术是尾部出血时间（TBT）和隐静脉出血（SVB）模型。本文讨论了这些方法在止血评估中的应用，以及将小鼠作为研究人类止血的替代物的优点和局限性。
相似文献
1
Mouse models of hemostasis.
Platelets. 2020 May 18;31(4):417-422. doi: 10.1080/09537104.2020.1719056. Epub 2020 Jan 28.
2
Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein.
J Thromb Haemost. 2017 Sep;15(9):1829-1833. doi: 10.1111/jth.13766. Epub 2017 Aug 5.
3
Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition.
J Thromb Haemost. 2015 Mar;13(3):417-25. doi: 10.1111/jth.12802. Epub 2015 Jan 9.
4
Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model.
Med Princ Pract. 2009;18(3):165-9. doi: 10.1159/000204344. Epub 2009 Apr 6.
5
Factor XI promotes hemostasis in factor IX-deficient mice.
J Thromb Haemost. 2018 Oct;16(10):2044-2049. doi: 10.1111/jth.14243. Epub 2018 Aug 16.
6
Role of hemostatic factors in hepatic injury and disease: animal models de-liver.
J Thromb Haemost. 2016 Jul;14(7):1337-49. doi: 10.1111/jth.13327. Epub 2016 May 10.
7
A mouse bleeding model to study oral anticoagulants.
Thromb Res. 2014 May;133 Suppl 1(0 1):S6-8. doi: 10.1016/j.thromres.2014.03.003.
8
A microengineered vascularized bleeding model that integrates the principal components of hemostasis.
Nat Commun. 2018 Feb 6;9(1):509. doi: 10.1038/s41467-018-02990-x.
9
Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211018510. doi: 10.1177/10760296211018510.
10
In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.
J Thromb Haemost. 2017 Feb;15(2):375-387. doi: 10.1111/jth.13579.
引用本文的文献
1
Chlorocatechol-functionalized gelatin nanoparticles as a hemostatic agent with antimicrobial properties.
Acta Biomater. 2025 Aug 12. doi: 10.1016/j.actbio.2025.08.020.
2
Local Hemostatic and Wound-Healing Agent in a Liquid Dosage Form.
Bull Exp Biol Med. 2025 Jul 18. doi: 10.1007/s10517-025-06428-5.
3
A battery-free nanofluidic intracellular delivery patch for internal organs.
Nature. 2025 Apr 30. doi: 10.1038/s41586-025-08943-x.
4
DNMT3A regulates murine megakaryocyte-biased hematopoietic stem cell fate decisions.
Blood Adv. 2025 May 13;9(9):2285-2299. doi: 10.1182/bloodadvances.2024015061.
5
Murine vs. Human Osteoblast Responses to Coagulation and Inflammatory Factors: Reconsidering the Use of Animal Models in Hemophilia a Research.
Biomedicines. 2024 Nov 22;12(12):2666. doi: 10.3390/biomedicines12122666.
6
Assessment of anticoagulant safety and coagulation analysis in mice using the VETSCAN VSpro analyzer.
J Thromb Thrombolysis. 2025 Mar;58(3):427-432. doi: 10.1007/s11239-024-03066-y. Epub 2024 Dec 19.
7
The eccentric nature of the neointima.
J Thromb Haemost. 2024 Dec;22(12):3397-3399. doi: 10.1016/j.jtha.2024.08.005.
8
Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species.
Int J Mol Sci. 2024 Mar 20;25(6):3494. doi: 10.3390/ijms25063494.
9
Whole blood storage duration alters fibrinogen levels and thrombin formation.
J Trauma Acute Care Surg. 2024 Jul 1;97(1):39-47. doi: 10.1097/TA.0000000000004317. Epub 2024 Mar 27.
10
An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy.
Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2316170121. doi: 10.1073/pnas.2316170121. Epub 2024 Jan 22.
本文引用的文献
1
The central role of thrombin in bleeding disorders.
Blood Rev. 2019 Nov;38:100582. doi: 10.1016/j.blre.2019.05.006. Epub 2019 May 22.
2
A non-circulating pool of factor XI associated with glycosaminoglycans in mice.
J Thromb Haemost. 2019 Sep;17(9):1449-1460. doi: 10.1111/jth.14494. Epub 2019 Jun 17.
3
The mode of anesthesia influences outcome in mouse models of arterial thrombosis.
Res Pract Thromb Haemost. 2019 Feb 15;3(2):197-206. doi: 10.1002/rth2.12184. eCollection 2019 Apr.
4
Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
Mol Ther. 2019 Jul 3;27(7):1228-1241. doi: 10.1016/j.ymthe.2019.03.016. Epub 2019 Mar 30.
5
Assessing Blood Clotting and Coagulation Factors in Mice.
Curr Protoc Mouse Biol. 2019 Jun;9(2):e61. doi: 10.1002/cpmo.61. Epub 2019 Mar 15.
6
Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24. doi: 10.1161/ATVBAHA.118.311655.
7
Plasma contact factors as therapeutic targets.
Blood Rev. 2018 Nov;32(6):433-448. doi: 10.1016/j.blre.2018.04.001. Epub 2018 Apr 12.
8
Small molecule targeting the Rac1-NOX2 interaction prevents collagen-related peptide and thrombin-induced reactive oxygen species generation and platelet activation.
J Thromb Haemost. 2018 Oct;16(10):2083-2096. doi: 10.1111/jth.14240. Epub 2018 Aug 13.
9
Factor XI promotes hemostasis in factor IX-deficient mice.
J Thromb Haemost. 2018 Oct;16(10):2044-2049. doi: 10.1111/jth.14243. Epub 2018 Aug 16.
10
A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss.
BMC Biotechnol. 2018 Apr 5;18(1):21. doi: 10.1186/s12896-018-0431-4.
Zotero 插件